{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-010469","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.900056+00:00","generated_at":"2026-06-17T06:15:48.162061+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"FDA grants barrier-to-innovation waiver; Cumberland to receive ~$1.9M refund for RediTrex fees","bullets":["FDA reversed prior denial and granted barrier-to-innovation waiver on March 30, 2023, after reconsideration request.","Refund of approximately $1.9 million in prescription drug program fees for RediTrex expected within 45 days.","Waiver tied to Cumberland's ifetroban clinical programs addressing unmet medical needs.","Original $1.9M fee paid Oct 4, 2021; initial denial Nov 1, 2021; reconsideration filed Nov 28, 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-010469","json":"https://secwatch.observer/filing/0001628280-23-010469.json","markdown":"https://secwatch.observer/filing/0001628280-23-010469.md","text":"https://secwatch.observer/filing/0001628280-23-010469.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023010469/0001628280-23-010469-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023010469/cpix-20230404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T06:15:48.162061+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}